(WO/2004/011029) PHARMACEUTICAL COMPOSITIONS FOR PENIS ENLARGEMENT
Historically, relaxin has been classified as a"pregnancy hormone"that acts on reproductive tissues only during pregnancy, preparing the female for parturition by "relaxing"the pelvic ligaments and tendons. However, recent evidence suggests that relaxin may be classified as a"master hormone"that also induces biochemical changes in a number of non-reproductive tissues
Relaxin directly and indirectly triggers a cascade of complex biochemical and cellular effects that can cause general morphological changes to genitalia.
The potentiator may be an agent which activates the androgen receptor, which is involved with male sexual development and function. For example, the potentiator may be an androgen hormone such as, but not limited to, the naturally occurring androgens and derivatives thereof, including androsterone, androsterone acetate, androsterone propionate, androsterone benzoate, androstenediol, androstenediol-3-acetate, androstenediol-17- acetate, androstenediol-3,17-diacetate, androstenediol-17-benzoate, androstenediol-3- acetate-17-benzoate, androstenedione, dehydroepiandrosterone (DHEA; also termed "prasterone")
The firmness of the penis generally decreases over this period, but will be at least 40% engorged for at least 3 and preferably up to 6 hours and less than 75% engorged for the majority of the time. The treatment is repeated over a period of time sufficient to cause a permanent increase in the length and girth of the patient's penis. The treatment may comprise administration with the composition alone, or in conjunction with potentiator. For example, the treatment may be repeated daily or at least two times a week over a period of several weeks or at least one month. More preferably, the treatment may be repeated at least 3-4 times a week for a period of at least 3 months. For treatment periods of between 12 and 18 months, an increase of at least 5% may be achieved in the length and girth of an erect penis, and increases of at least 30% or even at least 50% in the length and girth of an erect penis may be achieved. Active treatment for more extended periods, e. g. 24 months, may yield greater results.
CIPO - Patent - 2486714
The following experimental examples are illustrative of the use of this invention.
Example 1 A male patient, age 41, was treated with intracavernosal injections of a vasodilator, prostaglandin El, on a regular basis (approximately four to five times per week) over an 18 month treatment period. A sufficient quantity was administered to maintain a prolonged engorgement of an erectile response between 40-75% over a period of several hours, generally 3 to 6 hours. The quantity of medication was adjusted from time to time in accordance with the patient's response, which was monitored at least weekly.
The size of the patient's fully erect penis increased from 5.8 inches to 8.6 inches in length (about an 48% increase) and 3.7 inches to 5.8 inches in girth (about an 56% increase) over the 18-month treatment period. Following the discontinuation of this treatment, the erect penis length remained stable for two years at over 8 1/2 inches. Treatment was re- institued combining intracavemosal injections 3-4 times per week of a mixture of testosterone (0.5 mg) and vasodilators with low dose oral Potaba (500-1000 mg) 3-4 times per day. After a short treatment period of 2 1/2 months, the patient's erect penis was over 9 inches in length, which means he has gained an additional 0.4-0. 5 inches in length (about an 6% increase). The total increase in length was therefore about 3.2 inches (about an 55% increase) in length.
Example 2 A male patient, age 30, was treated with intracavemosal injections of the vasodilator on a regular basis (approximately four to five times per week) over a 6-month treatment period. A sufficient quantity was administered to maintain a prolonged engorgement over a period of about 3 to 6 hours. The quantity of medication was adjusted in accordance with the patient's response. The potentiator potaba (aminobenzoate) (1000 mg/4 times per day) was administered orally to the patient for the last 60 days of treatment.
Example 1 A male patient, age 41, was treated with intracavernosal injections of a vasodilator, prostaglandin El, on a regular basis (approximately four to five times per week) over an 18 month treatment period. A sufficient quantity was administered to maintain a prolonged engorgement of an erectile response between 40-75% over a period of several hours, generally 3 to 6 hours. The quantity of medication was adjusted from time to time in accordance with the patient's response, which was monitored at least weekly.
The size of the patient's fully erect penis increased from 5.8 inches to 8.6 inches in length (about an 48% increase) and 3.7 inches to 5.8 inches in girth (about an 56% increase) over the 18-month treatment period. Following the discontinuation of this treatment, the erect penis length remained stable for two years at over 8 1/2 inches. Treatment was re- institued combining intracavemosal injections 3-4 times per week of a mixture of testosterone (0.5 mg) and vasodilators with low dose oral Potaba (500-1000 mg) 3-4 times per day. After a short treatment period of 2 1/2 months, the patient's erect penis was over 9 inches in length, which means he has gained an additional 0.4-0. 5 inches in length (about an 6% increase). The total increase in length was therefore about 3.2 inches (about an 55% increase) in length.
Example 2 A male patient, age 30, was treated with intracavemosal injections of the vasodilator on a regular basis (approximately four to five times per week) over a 6-month treatment period. A sufficient quantity was administered to maintain a prolonged engorgement over a period of about 3 to 6 hours. The quantity of medication was adjusted in accordance with the patient's response. The potentiator potaba (aminobenzoate) (1000 mg/4 times per day) was administered orally to the patient for the last 60 days of treatment.
Historically, relaxin has been classified as a"pregnancy hormone"that acts on reproductive tissues only during pregnancy, preparing the female for parturition by "relaxing"the pelvic ligaments and tendons. However, recent evidence suggests that relaxin may be classified as a"master hormone"that also induces biochemical changes in a number of non-reproductive tissues
Relaxin directly and indirectly triggers a cascade of complex biochemical and cellular effects that can cause general morphological changes to genitalia.
The potentiator may be an agent which activates the androgen receptor, which is involved with male sexual development and function. For example, the potentiator may be an androgen hormone such as, but not limited to, the naturally occurring androgens and derivatives thereof, including androsterone, androsterone acetate, androsterone propionate, androsterone benzoate, androstenediol, androstenediol-3-acetate, androstenediol-17- acetate, androstenediol-3,17-diacetate, androstenediol-17-benzoate, androstenediol-3- acetate-17-benzoate, androstenedione, dehydroepiandrosterone (DHEA; also termed "prasterone")
The firmness of the penis generally decreases over this period, but will be at least 40% engorged for at least 3 and preferably up to 6 hours and less than 75% engorged for the majority of the time. The treatment is repeated over a period of time sufficient to cause a permanent increase in the length and girth of the patient's penis. The treatment may comprise administration with the composition alone, or in conjunction with potentiator. For example, the treatment may be repeated daily or at least two times a week over a period of several weeks or at least one month. More preferably, the treatment may be repeated at least 3-4 times a week for a period of at least 3 months. For treatment periods of between 12 and 18 months, an increase of at least 5% may be achieved in the length and girth of an erect penis, and increases of at least 30% or even at least 50% in the length and girth of an erect penis may be achieved. Active treatment for more extended periods, e. g. 24 months, may yield greater results.
CIPO - Patent - 2486714
Comment